—
C+
C+ The full Closelook — membership. Open the C+ overview

UCB SA (UCB.BR) — the peer cohort

As of 2026-09-22 — scores re-bake nightly. Cohort = shared Closelook index membership first, then sector. Diary readings, not advice.

UCB SA ranks 5 of 7 in its cohort on the Closelook composite (60/100) — the cohort is led by BB Biotech AG at 74/100.

NameCompositeMomentumQualityValuationSignalOff 52w high
UCB.BR UCB SA 60 16 70 58 warn 25.9%
BION.SW BB Biotech AG 74 70 96 80 info 8.4%
ARGX.BR Argen-X 64 76 75 27 ok 7.5%
ARGX argenx NV ADR 64 75 74 26 ok 10.2%
ONC BeiGene, Ltd. 64 80 64 31 ok 4.4%
REGN Regeneron Pharmaceuticals Inc 60 65 71 50 bull 7.1%
CAI Caris Life Sciences, Inc. Common Stock 59 81 60 30 ok 6.5%

Scores are relative readings across the Closelook coverage universe — methodology in the company-scoring explainer. Signal lights come from the nightly signal board.

FAQ · from the current data · as of 2026-09-22

Quick answers

Who are UCB SA's peers in the Closelook universe?

The cohort is drawn from shared Closelook index membership first, then sector: BB Biotech AG (BION.SW), Argen-X (ARGX.BR), argenx NV ADR (ARGX), BeiGene, Ltd. (ONC), Regeneron Pharmaceuticals Inc (REGN), Caris Life Sciences, Inc. Common Stock (CAI).

How does UCB.BR score against its peers?

UCB SA's composite reads 60/100, ranking 5 of 7 in its cohort as of 2026-09-22; the cohort's highest composite is BB Biotech AG at 74/100. Closelook scores are research diary readings, not ratings or advice.

Related in the Closelook universe

then Biotechnology. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.